![Jan Mikkelsen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jan Mikkelsen
Gründer bei
ASCENDIS PHARMA A/S
Vermögen: 102 Mio $ am 31.05.2026
Profil
Herr Jan M. Mikkelsen ist Chief Executive Officer & Director bei Ascendis Pharma Endocrinology Division A/S, President, CEO & Executive Director bei Ascendis Pharma A/S, Chief Executive Officer bei Ascendis Pharma Bone Diseases A/S und Chief Executive Officer bei Ascendis Pharma Growth Disorders AS. Er ist Mitglied des Board of Directors bei Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma A/S und Visen Pharmaceuticals (Shanghai) Co. Ltd. Herr Mikkelsen war zuvor als President & Chief Executive Officer bei LifeCycle Pharma A/S, als President-Pharmaceutical Division bei Maxygen, Inc., als Co-Chief Executive Officer bei Profound Pharma AS und als Vice President-Protein Discovery bei Novo Nordisk A/S tätig. Er erhielt seinen Bachelor-Abschluss von der University of Southern Denmark.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ASCENDIS PHARMA A/S -.--% | 18.03.2026 | 453’403 ( -.--% ) | 102 Mio $ | 31.05.2026 |
Aktive Positionen von Jan Mikkelsen
| Unternehmen | Position | Beginn |
|---|---|---|
| ASCENDIS PHARMA A/S | Gründer | 21.09.2006 |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Manufactures endocrine pharmaceutical products | Vorstandsvorsitzender | 29.06.2012 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Direktor/Vorstandsmitglied | - |
Ascendis Pharma Bone Diseases A/S | Vorstandsvorsitzender | - |
Ascendis Pharma Growth Disorders AS | Vorstandsvorsitzender | - |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Berater | 01.01.2022 |
Hummingbird Bioscience Holdings Pte Ltd.
 Hummingbird Bioscience Holdings Pte Ltd. MiscellaneousMiscellaneous Functions as an investment holding company | Vorsitzender | 01.01.2021 |
Ehemalige bekannte Positionen von Jan Mikkelsen
| Unternehmen | Position | Ende |
|---|---|---|
| VISEN PHARMACEUTICALS | Direktor/Vorstandsmitglied | 27.06.2025 |
| VELOXIS PHARMACEUTICALS A/S | Vorstandsvorsitzender | 01.01.2006 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░░░░░░ | - |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Jan Mikkelsen
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
66
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Finance |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
University of Southern Denmark
 University of Southern Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Manufactures endocrine pharmaceutical products | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Health Technology |
Ascendis Pharma Bone Diseases A/S | |
Hummingbird Bioscience Holdings Pte Ltd.
Hummingbird Bioscience Holdings Pte Ltd. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Ascendis Pharma Growth Disorders AS | |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
